Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000737:chemistry* / Q000145:classification / Q000401:mortality / Q000473:pathology; D002277:Carcinoma / Q000737:chemistry* / Q000145:classification / Q000401:mortality / Q000473:pathology; D004268:DNA-Binding Proteins / Q000032:analysis*; D018572:Disease-Free Survival; D020847:Estrogen Receptor Modulators / Q000627:therapeutic use; D004967:Estrogens; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D009361:Neoplasm Invasiveness; D009376:Neoplasms, Hormone-Dependent / Q000737:chemistry / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D009687:Nuclear Proteins / Q000032:analysis*; D011379:Prognosis; D016016:Proportional Hazards Models; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D011960:Receptors, Estrogen / Q000032:analysis*; D012306:Risk; D016019:Survival Analysis; D013629:Tamoxifen / Q000627:therapeutic use; D051840:Y-Box-Binding Protein 1
D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; D020847:Estrogen Receptor Modulators; D004967:Estrogens; D009687:Nuclear Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D013629:Tamoxifen; D051840:Y-Box-Binding Protein 1; C070856:YBX1 protein, human